Genentech: Jacqueline M McBride | Senior Scientist, OMNI Biomarker Development

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/jacqueline-m-mcbride

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"Imagination is more important than knowledge"

Years at Genentech

Publications

Awards & Honors

I am native Scot and Basic Immunologist. I began my science career at the university of Glasgow in one of the first Immunology degree courses offered in the UK. I continued to grow my passion for science in Europe at the IMP Biocenter in Vienna looking to understand the mechanisms of dendritic cell tolerance. From here I sought to expand my knowledge in Clinical Immunology at Stanford School of medicine and then joined the postdoctoral program at Genentech in Immunology discovery. I soon realized my passion and curiosity was in biotechnology and translational science and joined the OMNI-Biomarker development group in Development Sciences as a Scientist. I currently work as a Scientist and a Biomarker Subteam leader and supporting the development of novel therapeutics such as Influenza A, Etrolizumab, and anti- PD-L1 combos.

Featured Publication

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.

Arthritis Rheum. 2012 Nov;64(11):3666-76.

McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J.

View Abstract

I am currently a Scientist and Biomarker subteam leader for both early and late stage development molecules. Internally I collaborate with many functions from research through development to drive the delivery of a safe and efficacious product. Externally I also engage with global thought leaders and investigators, which allows the generation of vital knowledge and technologies in specialized patient populations that inform the development of our clinical candidates. I am accountable for the delivery of both predictive and pharmacodynamics biomarker strategies, providing high quality assays and data. These goal of my work is to enable decision making including refining our knowledge of the MOA of a given molecule, inform dose selection, demonstrating proof of activity in pre-clinical and clinical studies, and mechanistic differentiation from competitor molecules. I am fortunate to have worked in many disease indications including Autoimmune diseases, infectious Diseases and Oncology.

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Blood Cancer Journal,

A. Keith Stewart; Amrita Y. Krishnan; Seema Singhal; Ralph V. Boccia; Manish R. Patel; Ruben Niesvizky; Chanan-Khan; Sikander Ailawadhi; Jochen Brumm; Kirsten Mundt; Kyu Hong; Jacqueline McBride; Quyen Shon-Nguyen; Yuanyuan Xiao; Vanitha Ramakrishnan; Andy Polson; Divya Samineni; Douglas Leipold; Eric Humke; James Scott McClellan; Jesus G. Berdeja

Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease

Frontiers in Pharmacology,

Charlotte Lichnog; Sha Klabunde; Emily Becker; Franklin Fuh; Philipp Tripal; Raja Atreya; Entcho Klenske; Rich Erickson; Henry Chiu; Chae Reed; Shan Chung; Clemens Neufert; Imke Atreya; Jacqueline McBride; Markus F. Neurath; Sebastian Zundler

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, ISSN: 13652036 02692813

Meina Tao Tang; Mary Keir; Rich Erickson; Eric Stefanich; Franklin Fuh; Teresa Ramirez Montagut; Jacqueline McBride; Dimitry Danilenko

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Jacqueline M McBride

Senior Scientist, OMNI Biomarker Development

Featured Publication

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.